Get the Stockscreener App
0.2941
3.19%
0.0091
Pre-market:
.29
-0.0041
-1.39%
Azitra Inc stock is traded at $0.2941, with a volume of 610.12K.
It is up +3.19% in the last 24 hours and down -10.77% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.285
Open:
$0.2791
24h Volume:
610.12K
Relative Volume:
0.25
Market Cap:
$3.16M
Revenue:
$1.27M
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.0131
EPS:
-22.4496
Net Cash Flow:
$-10.46M
1W Performance:
-14.68%
1M Performance:
-10.77%
6M Performance:
+12.25%
1Y Performance:
-25.58%
1-Day Range:
$0.278
$0.3155
1-Week Range:
$0.278
$0.3373
52-Week Range:
$0.1305
$1.40
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.2941 | 3.06M | 1.27M | -11.28M | -10.46M | -22.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Azitra Inc Stock (AZTR) Latest News
Highs Report: Will Azitra Inc. stock see PE expansionJuly 2025 Analyst Calls & Risk Controlled Daily Trade Plans - ulpravda.ru
Why analysts upgrade Azitra Inc. stockQuarterly Growth Report & Technical Entry and Exit Tips - ulpravda.ru
Is Azitra Inc. stock a buy for dividend growth2025 Breakouts & Breakdowns & Weekly Return Optimization Alerts - ulpravda.ru
Is Azitra Inc stock positioned for secular growth2025 Price Momentum & Real-Time Volume Analysis - ulpravda.ru
Will Azitra Inc. stock attract ESG investorsJuly 2025 Catalysts & Long-Term Growth Plans - ulpravda.ru
Azitra (AZTR) filing shows Alumni Capital 9.99% beneficial holding - Stock Titan
How Azitra Inc. stock benefits from tech adoptionJuly 2025 Market Mood & AI Powered Buy and Sell Recommendations - DonanımHaber
Bear Alert: How Azitra Inc. stock benefits from tech adoptionJuly 2025 Drop Watch & Risk Managed Investment Signals - Bölüm Sonu Canavarı
Will Azitra Inc. stock see PE expansionPortfolio Return Summary & Real-Time Market Sentiment Reports - ulpravda.ru
Aug Action: Will Azitra Inc. stock attract ESG investorsJuly 2025 Chart Watch & AI Optimized Trade Strategies - ulpravda.ru
Is Azitra Inc. stock positioned for digital transformationEarnings Beat & Consistent Return Investment Signals - Улправда
Why Azitra Inc stock is favored by hedge fundsWeekly Market Outlook & Community Trade Idea Sharing - ulpravda.ru
Aug Final Week: Will Azitra Inc. stock attract ESG investorsPortfolio Return Summary & Daily Oversold Bounce Ideas - ulpravda.ru
Azitra receives approval for NYSE American compliance plan - Investing.com
Azitra Inc Compliance Plan Approved by NYSE American - TipRanks
Azitra says NYSE American approves compliance plan - TipRanks
Azitra receives NYSE American approval of listing compliance plan - MSN
Azitra receives approval for NYSE American compliance plan By Investing.com - Investing.com South Africa
Azitra (NYSE: AZTR) outlines NYSE American compliance plan after equity notice - Stock Titan
Azitra receives notice of acceptance of the listing standards compliance plan from NYSE American - marketscreener.com
Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American - PR Newswire
Azitra files to sell 38.9M shares of common stock for holders - MSN
Azitra (NYSEAMERICAN:AZTR) Trading Down 4.7% – Here’s Why - Defense World
Azitra Inc (AZTR) -5.33% in After-hours: Declines Despite Recent Developments - Stocks Telegraph
Azitra (NYSE: AZTR) files S-1 for 51.8M resale shares under Alumni Capital deals - Stock Titan
Trade Report: Why analysts upgrade Azitra Inc stock2025 Top Gainers & Verified Short-Term Plans - moha.gov.vn
Azitra (AZTR) Price Target Decreased by 77.48% to 2.75 - Nasdaq
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jasper Therapeutics (JSPR) and Azitra Inc (AZTR) - The Globe and Mail
How Azitra Inc stock reacts to weak economyWeekly Risk Report & Accurate Technical Buy Alerts - Newser
Can Azitra Inc stock attract ESG investmentsEntry Point & Scalable Portfolio Growth Ideas - Newser
Will Azitra Inc stock top growth indexesPortfolio Risk Summary & Real-Time Sentiment Analysis - Newser
Azitra Inc (AZTR) Stock Price | Live Quotes & Charts | AMEX - StocksToTrade
MSN Money - MSN
Azitra prices 4.69M share private placement at 32c per share - MSN
Azitra Receives Notice of Non-Compliance from NYSE American (PR Newswire) - Aktiellt
You might want to take a look at Azitra Inc (AZTR) now - Setenews
Azitra Inc Secures $1.5M in Private Placement - MSN
Azitra, Inc. Announces Reverse Stock Split (PR Newswire) - Aktiellt
Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash (PR Newswire) - Aktiellt
[8-K] Azitra, Inc. Reports Material Event | AZTR SEC FilingForm 8-K - Stock Titan
Azitra announces $1.5 million private placement at premium to market By Investing.com - Investing.com Nigeria
Azitra announces $1.5 million private placement at premium to market - Investing.com India
Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules - Finviz
Netherton Syndrome Market is Going to Booming Growth 2025-2032 | - openPR.com
Azitra, Inc. announced that it expects to receive $1.5 million in funding - MarketScreener
Can Azitra Inc stock stage a strong rebound this quarterJuly 2025 PreEarnings & Risk Controlled Daily Plans - newser.com
Is Azitra Inc stock testing key supportDay Trade & Free Verified High Yield Trade Plans - newser.com
Why institutional investors increase stakes in Azitra Inc stockWeekly Loss Report & Verified Momentum Watchlists - newser.com
Zacks Small Cap Issues Positive Estimate for Azitra Earnings - Defense World
Is Azitra Inc stock attractive for dividend growthStock Surge & Scalable Portfolio Growth Ideas - newser.com
Is Azitra Inc. stock a smart buy before Fed meeting2025 Retail Activity & Fast Exit Strategy with Risk Control - newser.com
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
Cap:
|
Volume (24h):